Realta Investment Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Realta Investment Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-140	Closed	-$49K	–	370
2019 Q4	$49K	Sell	140 -9	-6%	-$3.1K	0.01%	666
2019 Q3	$52K	Sell	149 -14	-9%	-$5.22K	0.01%	662
2019 Q2	$82K	Buy	163 +21	+15%	+$14.8K	0.02%	551
2019 Q1	$142K	Buy	+142	New	+$132K	0.06%	335

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Realta Investment Advisors's ATRA Position: Q1 2020 in Review

Realta Investment Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2020, closing a stake of 140 shares — an estimated $49K sold.

Realta Investment Advisors first reported a position in ATRA in Q1 2019 and held it in 4 quarters. The position peaked at $142K in Q1 2019. 111 funds tracked by Wall St. Rank hold ATRA as of Q1 2020.

Realta Investment Advisors reported no remaining Atara Biotherapeutics position as of Q1 2020 after selling out during the quarter.
Realta Investment Advisors sold 140 Atara Biotherapeutics shares in Q1 2020, an estimated $49K.
Realta Investment Advisors first reported a position in Atara Biotherapeutics in Q1 2019 and held it in 4 quarters.
Realta Investment Advisors's Atara Biotherapeutics position peaked at $142K in Q1 2019.
111 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2020.

Based on Realta Investment Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.